Brandi Johnston
Adult Health · Jackson, MSNPI 1497271415
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,862 of the $6,798 with a category attached, or 86.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $25.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$969
- AbbVie$725
- Pfizer$610
- SK Life Science, Inc.$464
- Lundbeck LLC$453
- Acadia Pharmaceuticals Inc$440
- plus $3K from 28 others
What the payments were for
- Travel & lodging$91814%
- Food & beverage$5,86286%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 4 | $969 |
| AbbVie | 38 | $725 |
| Pfizer | 33 | $610 |
| SK Life Science, Inc. | 16 | $464 |
| Lundbeck LLC | 27 | $453 |
| Acadia Pharmaceuticals Inc | 19 | $440 |
| AstraZeneca | 13 | $414 |
| UCB, Inc. | 16 | $356 |
| Argenx US, Inc. | 14 | $345 |
| Merz Pharmaceuticals, LLC | 11 | $309 |
| Neurocrine Biosciences, Inc. | 9 | $248 |
| Otsuka America Pharmaceutical, Inc. | 9 | $216 |
| Biogen | 8 | $207 |
| CSL Behring | 4 | $100 |
| Lilly USA, LLC | 6 | $99 |
| Neurelis, Inc. | 4 | $96 |
| Teva Pharmaceuticals USA, Inc. | 5 | $88 |
| Amneal Pharmaceuticals LLC | 5 | $86 |
| Catalyst Pharmaceuticals, Inc. | 3 | $77 |
| Acorda Therapeutics, Inc | 3 | $77 |
| Sumitomo Pharma America, Inc. | 3 | $62 |
| ANI Pharmaceuticals, Inc. | 3 | $56 |
| MDD US Operations, LLC | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Eisai Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Amylyx Pharmaceuticals, Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Amgen | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Cala Health, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$918
How this compares
$6,798 in reported general payments places this provider in the 90th percentile of 93 adult health providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $21,011 |
| EliquisApixaban | 16 | $11,745 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,946 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,358 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,705 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,420 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,607 |
| Levetiracetam | 63 | $1,513 |
| Lacosamide | 20 | $1,225 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $577 |
| ClopidogrelClopidogrel Bisulfate | 38 | $420 |
| Zonisamide | 15 | $402 |
| Gabapentin | 19 | $373 |
| Fluticasone Propionate | 21 | $318 |
| Divalproex Sodium | 14 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $610 | $11,74516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 93 adult health providers in Mississippi.
Other adult health in Jackson
- Keila BrownJackson$7K
- Deborah HoodJackson$4K
- Ashley FitzhughJackson$4K
- Frances WoodwardJackson$3K
- Candice ColemanJackson$3K
- Nina WaltzerJackson$1K
- Gretchen ShullJackson$818
- Janice HuffJackson$585
- Chatina MartinJackson$478
- Gwendolyn McAlpineJackson$425
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.